Considering of the prognosis differences between two types of CEBPA mutations, the causal relationship between SLC22A3 hypermethylation and CEBPA mutation and its clinical significance in AML remain to be clarified. This evidence concerns the gene SLC22A3 and acute myeloid leukemia.